- Home
- XPRO vs CVAC Comparison
XPRO vs CVAC Comparison
Compare XPRO & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- CVAC
- Stock Information
- Founded
- XPRO 1938
- CVAC 2000
- Country
- XPRO United States
- CVAC Germany
- Employees
- XPRO N/A
- CVAC N/A
- Industry
- XPRO Oilfield Services/Equipment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- CVAC Health Care
- Exchange
- XPRO Nasdaq
- CVAC Nasdaq
- Market Cap
- XPRO 1.4B
- CVAC 1.2B
- IPO Year
- XPRO 2013
- CVAC 2020
- Fundamental
- Price
- XPRO $12.42
- CVAC $5.39
- Analyst Decision
- XPRO Buy
- CVAC Hold
- Analyst Count
- XPRO 4
- CVAC 3
- Target Price
- XPRO $12.50
- CVAC $6.83
- AVG Volume (30 Days)
- XPRO 1.1M
- CVAC 619.8K
- Earning Date
- XPRO 10-23-2025
- CVAC 08-15-2025
- Dividend Yield
- XPRO N/A
- CVAC N/A
- EPS Growth
- XPRO N/A
- CVAC N/A
- EPS
- XPRO 0.61
- CVAC 1.01
- Revenue
- XPRO $1,673,283,000.00
- CVAC $599,540,810.00
- Revenue This Year
- XPRO N/A
- CVAC N/A
- Revenue Next Year
- XPRO $3.65
- CVAC $24.04
- P/E Ratio
- XPRO $20.67
- CVAC $5.37
- Revenue Growth
- XPRO 2.67
- CVAC 675.15
- 52 Week Low
- XPRO $6.70
- CVAC $2.37
- 52 Week High
- XPRO $18.76
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- XPRO 63.38
- CVAC 49.09
- Support Level
- XPRO $11.92
- CVAC $5.33
- Resistance Level
- XPRO $12.64
- CVAC $5.48
- Average True Range (ATR)
- XPRO 0.46
- CVAC 0.04
- MACD
- XPRO -0.00
- CVAC -0.01
- Stochastic Oscillator
- XPRO 85.40
- CVAC 38.89
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.